Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Cash from Financing Activities: 2014-2024

Historic Cash from Financing Activities for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Dec 2024 value amounting to $353.4 million.

  • Syndax Pharmaceuticals' Cash from Financing Activities rose 102.65% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $355.2 million, marking a year-over-year increase of 34.32%. This contributed to the annual value of $353.4 million for FY2024, which is 33.78% up from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Cash from Financing Activities stood at $353.4 million for FY2024, which was up 33.78% from $264.1 million recorded in FY2023.
  • Over the past 5 years, Syndax Pharmaceuticals' Cash from Financing Activities peaked at $353.4 million during FY2024, and registered a low of $118.5 million during FY2021.
  • In the last 3 years, Syndax Pharmaceuticals' Cash from Financing Activities had a median value of $264.1 million in 2023 and averaged $263.3 million.
  • In the last 5 years, Syndax Pharmaceuticals' Cash from Financing Activities soared by 965.54% in 2020 and then plummeted by 61.09% in 2021.
  • Syndax Pharmaceuticals' Cash from Financing Activities (Yearly) stood at $304.4 million in 2020, then tumbled by 61.09% to $118.5 million in 2021, then skyrocketed by 45.41% to $172.3 million in 2022, then soared by 53.34% to $264.1 million in 2023, then spiked by 33.78% to $353.4 million in 2024.